Trial Profile
Phase I open-label, dose-finding and escalation study to evaluate the pharmacokinetics, safety and tolerability of an intravenous formulation of rolapitant in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2015
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics
- 30 Sep 2013 Status changed from planning to recruiting, according to a TESARO media release.
- 30 Jul 2012 New trial record